Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies

Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 10; pp. 3269 - 3281
Main Authors Krystel-Whittemore, Melissa, Petrova-Drus, Kseniya, Ptashkin, Ryan N., Ewalt, Mark D., Yao, JinJuan, Liu, Ying, Zhu, Menglei, Benhamida, Jamal, Durham, Benjamin, Kumar, Jyoti, Nafa, Khedoudja, Kiecka, Iwona, Bowman, Anita S., Gedvilaite, Erika, Casanova, Jacklyn, Lin, Yun-Te, Mohanty, Abhinita S., Rana, Satshil, Rema, Anoop Balakrishnan, Rijo, Ivelise, Chaves, Nelio, Salazar, Paulo, Yun, Anita, Lachhander, Sean, Wang, Wei, Haque, Mohammad S., Xiao, Wenbin, Roshal, Mikhail, Giralt, Sergio, Salles, Gilles, Rampal, Raajit, Stein, Eytan M., Perales, Miguel-Angel, Horwitz, Steven, Jakubowski, Ann, Ponce, Doris, Markova, Alina, Birsoy, Ozge, Mandelker, Diana, Mantha, Simon, Dogan, Ahmet, Benayed, Ryma, Ladanyi, Marc, Berger, Michael F., Brannon, A. Rose, Zehir, Ahmet, Vanderbilt, Chad, Arcila, Maria E.
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.10.2024
Ferrata Storti Foundation
Subjects
Online AccessGet full text
ISSN0390-6078
1592-8721
1592-8721
DOI10.3324/haematol.2024.285054

Cover

Abstract Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process.
AbstractList Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patient management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs. In contrast to solid tumors, conventional sources of normal control (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we find nail cfDNA is a robust source of germline control for paired genomic studies. In a subset of patients, nail DNA may have tumor DNA contamination, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1482) compared to lymphoid diseases (5.4%; 61/1128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. For nails collected after allogeneic stem-cell transplantation, donor DNA was identified in 22% (11/50). In this cohort, an association with recent history of graft-vs-host disease was identified. These findings should be considered as a potential limitation for the use of nail as normal control but could also provide important diagnostic information regarding the disease process.
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process.
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients' management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process.Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients' management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process.
Author Lachhander, Sean
Rana, Satshil
Wang, Wei
Perales, Miguel-Angel
Ponce, Doris
Yun, Anita
Arcila, Maria E.
Durham, Benjamin
Gedvilaite, Erika
Krystel-Whittemore, Melissa
Rema, Anoop Balakrishnan
Ptashkin, Ryan N.
Kumar, Jyoti
Bowman, Anita S.
Salles, Gilles
Birsoy, Ozge
Zehir, Ahmet
Kiecka, Iwona
Giralt, Sergio
Lin, Yun-Te
Mantha, Simon
Roshal, Mikhail
Vanderbilt, Chad
Dogan, Ahmet
Brannon, A. Rose
Benayed, Ryma
Ladanyi, Marc
Markova, Alina
Petrova-Drus, Kseniya
Zhu, Menglei
Xiao, Wenbin
Benhamida, Jamal
Jakubowski, Ann
Nafa, Khedoudja
Mandelker, Diana
Casanova, Jacklyn
Liu, Ying
Mohanty, Abhinita S.
Stein, Eytan M.
Ewalt, Mark D.
Rampal, Raajit
Salazar, Paulo
Haque, Mohammad S.
Chaves, Nelio
Yao, JinJuan
Rijo, Ivelise
Berger, Michael F.
Horwitz, Steven
AuthorAffiliation 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 Department of Pathology and Laboratory Medicine
AuthorAffiliation_xml – name: 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– name: 1 Department of Pathology and Laboratory Medicine
Author_xml – sequence: 1
  givenname: Melissa
  surname: Krystel-Whittemore
  fullname: Krystel-Whittemore, Melissa
– sequence: 2
  givenname: Kseniya
  surname: Petrova-Drus
  fullname: Petrova-Drus, Kseniya
– sequence: 3
  givenname: Ryan N.
  surname: Ptashkin
  fullname: Ptashkin, Ryan N.
– sequence: 4
  givenname: Mark D.
  surname: Ewalt
  fullname: Ewalt, Mark D.
– sequence: 5
  givenname: JinJuan
  surname: Yao
  fullname: Yao, JinJuan
– sequence: 6
  givenname: Ying
  surname: Liu
  fullname: Liu, Ying
– sequence: 7
  givenname: Menglei
  surname: Zhu
  fullname: Zhu, Menglei
– sequence: 8
  givenname: Jamal
  surname: Benhamida
  fullname: Benhamida, Jamal
– sequence: 9
  givenname: Benjamin
  surname: Durham
  fullname: Durham, Benjamin
– sequence: 10
  givenname: Jyoti
  surname: Kumar
  fullname: Kumar, Jyoti
– sequence: 11
  givenname: Khedoudja
  surname: Nafa
  fullname: Nafa, Khedoudja
– sequence: 12
  givenname: Iwona
  surname: Kiecka
  fullname: Kiecka, Iwona
– sequence: 13
  givenname: Anita S.
  surname: Bowman
  fullname: Bowman, Anita S.
– sequence: 14
  givenname: Erika
  surname: Gedvilaite
  fullname: Gedvilaite, Erika
– sequence: 15
  givenname: Jacklyn
  surname: Casanova
  fullname: Casanova, Jacklyn
– sequence: 16
  givenname: Yun-Te
  surname: Lin
  fullname: Lin, Yun-Te
– sequence: 17
  givenname: Abhinita S.
  surname: Mohanty
  fullname: Mohanty, Abhinita S.
– sequence: 18
  givenname: Satshil
  surname: Rana
  fullname: Rana, Satshil
– sequence: 19
  givenname: Anoop Balakrishnan
  surname: Rema
  fullname: Rema, Anoop Balakrishnan
– sequence: 20
  givenname: Ivelise
  surname: Rijo
  fullname: Rijo, Ivelise
– sequence: 21
  givenname: Nelio
  surname: Chaves
  fullname: Chaves, Nelio
– sequence: 22
  givenname: Paulo
  surname: Salazar
  fullname: Salazar, Paulo
– sequence: 23
  givenname: Anita
  surname: Yun
  fullname: Yun, Anita
– sequence: 24
  givenname: Sean
  surname: Lachhander
  fullname: Lachhander, Sean
– sequence: 25
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
– sequence: 26
  givenname: Mohammad S.
  surname: Haque
  fullname: Haque, Mohammad S.
– sequence: 27
  givenname: Wenbin
  surname: Xiao
  fullname: Xiao, Wenbin
– sequence: 28
  givenname: Mikhail
  surname: Roshal
  fullname: Roshal, Mikhail
– sequence: 29
  givenname: Sergio
  surname: Giralt
  fullname: Giralt, Sergio
– sequence: 30
  givenname: Gilles
  surname: Salles
  fullname: Salles, Gilles
– sequence: 31
  givenname: Raajit
  surname: Rampal
  fullname: Rampal, Raajit
– sequence: 32
  givenname: Eytan M.
  surname: Stein
  fullname: Stein, Eytan M.
– sequence: 33
  givenname: Miguel-Angel
  surname: Perales
  fullname: Perales, Miguel-Angel
– sequence: 34
  givenname: Steven
  surname: Horwitz
  fullname: Horwitz, Steven
– sequence: 35
  givenname: Ann
  surname: Jakubowski
  fullname: Jakubowski, Ann
– sequence: 36
  givenname: Doris
  surname: Ponce
  fullname: Ponce, Doris
– sequence: 37
  givenname: Alina
  surname: Markova
  fullname: Markova, Alina
– sequence: 38
  givenname: Ozge
  surname: Birsoy
  fullname: Birsoy, Ozge
– sequence: 39
  givenname: Diana
  surname: Mandelker
  fullname: Mandelker, Diana
– sequence: 40
  givenname: Simon
  surname: Mantha
  fullname: Mantha, Simon
– sequence: 41
  givenname: Ahmet
  surname: Dogan
  fullname: Dogan, Ahmet
– sequence: 42
  givenname: Ryma
  surname: Benayed
  fullname: Benayed, Ryma
– sequence: 43
  givenname: Marc
  surname: Ladanyi
  fullname: Ladanyi, Marc
– sequence: 44
  givenname: Michael F.
  surname: Berger
  fullname: Berger, Michael F.
– sequence: 45
  givenname: A. Rose
  surname: Brannon
  fullname: Brannon, A. Rose
– sequence: 46
  givenname: Ahmet
  surname: Zehir
  fullname: Zehir, Ahmet
– sequence: 47
  givenname: Chad
  surname: Vanderbilt
  fullname: Vanderbilt, Chad
– sequence: 48
  givenname: Maria E.
  surname: Arcila
  fullname: Arcila, Maria E.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38450530$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhi1URLeFf4CQj1yyOP5IYi6oWihUquACZ8sZT7KuEnuxs5X493i7XUQ5cLGlmXee8XjeC3IWYkBCXtdsLQSX77YWZ7vEac0Zl2veKabkM7KqleZV1_L6jKyY0KxqWNudk4uc7xjjTOv2BTkXnSxywVZk3uA0VUNCpB-_XtEhxZkG6ycKk9_tfBgztZnmuE-ANA40xDTbko1hSXGiQ0x0xBBnDzQve-cxUx_o9vi0OJZwkfsx2AAl95I8H-yU8dXjfUl-XH_6vvlS3X77fLO5uq1Atmqpat60ylmAhkHvHJTJoEGwWAvWcKZcj07VCmorHBtcL6VudI89doqDc624JDdHrov2zuySn236ZaL15iEQ02hsWjxMaFQrGsGcaJ0GqbC3GrTVHSA25YSusD4cWbt9P6MDLJPb6Qn0aSb4rRnjvalrKYXQvBDePhJS_LnHvJjZZyj_bgPGfTZcS153nWhkkb75u9mfLqeFFcH7owBSzDnhYMAvdvGHfZS1mZqZgzvMyR3m4A5zdEcplv8Un_j_LfsNwrnD1A
CitedBy_id crossref_primary_10_3324_haematol_2024_285055
crossref_primary_10_3324_haematol_2024_285371
Cites_doi 10.1373/clinchem.2008.108225
10.1158/1055-9965.EPI-14-0552
10.1385/SCR:1:1:037
10.1038/s41467-023-42585-9
10.1038/nbt.2696
10.1373/clinchem.2006.085043
10.1016/j.cell.2006.07.024
10.1016/j.jmoldx.2014.02.004
10.1111/j.1467-2494.2007.00372.x
10.1016/j.bbmt.2010.09.001
10.1038/nature730
10.1097/00007691-200108000-00004
10.4236/ojepi.2015.51006
10.1186/2041-2223-2-23
10.1093/nar/9.17.4267
10.1007/s11864-023-01089-w
10.1371/journal.pone.0235146
10.1093/nar/gkw520
10.1038/s41409-020-0938-x
10.1038/ncb1132
10.1158/2159-8290.CD-11-0184
10.1177/10760296221097969
10.1182/bloodadvances.2020001636
10.1016/j.ajhg.2020.01.008
10.1164/rccm.200301-145OC
10.1177/154405910608501215
10.1006/excr.2000.5027
10.3390/ijms21113900
10.1038/nm.4333
10.1016/j.vibspec.2018.09.004
10.1016/S0002-9440(10)63203-8
10.1016/j.aanat.2011.03.013
10.1007/s00292-023-01234-0
10.1016/j.jmoldx.2014.12.006
10.1182/blood-2007-02-071423
10.1097/PAS.0b013e3180335f65
10.1038/s41598-018-31503-5
10.1016/j.clindermatol.2013.06.006
10.1016/j.tcb.2022.12.001
10.1038/s41525-022-00285-1
10.1016/S0140-6736(03)12894-2
10.1371/journal.pone.0017581
10.1158/1078-0432.1119.11.3
10.1038/35018642
10.1016/j.bbamcr.2013.06.010
10.7554/eLife.66395
10.3961/jpmph.2012.45.4.235
10.1038/sj.leu.2403789
10.1016/j.yjmcc.2021.07.004
10.1038/nature00870
10.1007/s004290050237
10.1007/s12024-018-0057-9
ContentType Journal Article
Copyright Copyright© 2024 Ferrata Storti Foundation
Copyright_xml – notice: Copyright© 2024 Ferrata Storti Foundation
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3324/haematol.2024.285054
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1592-8721
EndPage 3281
ExternalDocumentID oai_doaj_org_article_573630d37d9c45eba9c9a98cee698cc8
PMC11443392
38450530
10_3324_haematol_2024_285054
Genre Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA008748
GroupedDBID ---
29I
2WC
53G
5GY
5RE
5VS
AAFWJ
AAYXX
ADBBV
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BTFSW
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GROUPED_DOAJ
H13
HYE
KQ8
OK1
OVT
P2P
RHI
RNS
RPM
SJN
TFS
TR2
W8F
WOQ
WOW
NPM
7X8
5PM
ID FETCH-LOGICAL-c475t-12675dacc60cbddc054c6ecae1306205dbed515c1a3d0fdb44969bebe852cdd73
IEDL.DBID DOA
ISSN 0390-6078
1592-8721
IngestDate Wed Aug 27 01:25:18 EDT 2025
Tue Sep 30 17:07:12 EDT 2025
Fri Sep 05 02:54:20 EDT 2025
Mon Jul 21 06:02:49 EDT 2025
Wed Oct 01 04:59:31 EDT 2025
Thu Apr 24 22:50:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License http://creativecommons.org/licenses/by-nc/4.0
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c475t-12675dacc60cbddc054c6ecae1306205dbed515c1a3d0fdb44969bebe852cdd73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
MK-W has been an advisory board member and speaker for AstraZeneca and has provided professional services for Foundation Medicine. KPD has received an honorarium (not related to this study) from Invivoscribe, Inc. RNP is an employee of C2i Genomics. RR has received consulting fees from Incyte Corporation, Celgene/BMS, Blueprint, AbbVie, CTI, Stemline, Galecto, Pharmaessentia, Constellation/Morphosys, Sierra Oncology/GSK, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, and Karyopharm and has received research funding from Constellation Pharmaceuticals, Ryvu, Zentalis, and Stemline Therapeutics. MAP reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma; he serves on Data Safety Monitoring Boards for Cidara Therapeutics, Medigene, and Sellas Life Sciences, and on a scientific advisory board of NexImmune; he has ownership interests in NexImmune, Omeros, and OrcaBio; and has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. SH is a consultant for Affimed, Abcuro Inc, Corvus, Daiichi Sankyo, Kyowa Hakko Kirin, ONO Pharmaceuticals, SeaGen, SecuraBio, Takeda, and Yingli; and has received research support from ADC Therapeutics, Affimed, C4, Celgene, Crispr Therapeutics, Daiichi Sankyo, Dren Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, and SecuraBio. DP has received honoraria from Incyte and Sanofi; has served on advisory boards for Evive Biotechnology (Shanghai) Ltd (formerly Generon [Shanghai] Corporation Ltd), Kadmon-Sanofi Corporation, Ceramedix, and Incyte; and has received research funding from Incyte Corporation and Sanofi. AM has received research funding from AstraZeneca, Incyte Corporation, Kintara Therapeutics, and Amryt Pharma; has provided consultancy services for ADC Therapeutics, Alira Health, AstraZeneca, Protagonist Therapeutics, OnQuality, and Janssen; and has received royalties from UpToDate. SM is the principal owner of Daboia Consulting LLC. AD receives research support from Roche and Takeda. MFB has provided consultancy services for Eli Lilly, AstraZeneca, and Paige.AI; has received research support from Boundless Bio; and has intellectual property rights with SOPHiA Genetics. CV holds equity and intellectual property rights with, and provides professional services and activities for Paige.AI. MEA has acted as a speaker for Biocartis, Invivoscribe, Physician Educational Resources (PER), Peerview Institute for Medical Education, Clinical Care Options, and RMEI Medical Education; and has acted as a consultant for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, Roche, Biocartis, and Sanofi.
Disclosures
OpenAccessLink https://doaj.org/article/573630d37d9c45eba9c9a98cee698cc8
PMID 38450530
PQID 2942188364
PQPubID 23479
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_573630d37d9c45eba9c9a98cee698cc8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11443392
proquest_miscellaneous_2942188364
pubmed_primary_38450530
crossref_citationtrail_10_3324_haematol_2024_285054
crossref_primary_10_3324_haematol_2024_285054
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-10-01
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: 2024-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Italy
PublicationPlace_xml – name: Italy
PublicationTitle Haematologica (Roma)
PublicationTitleAlternate Haematologica
PublicationYear 2024
Publisher Fondazione Ferrata Storti
Ferrata Storti Foundation
Publisher_xml – name: Fondazione Ferrata Storti
– name: Ferrata Storti Foundation
References 67188
67221
67189
67222
67182
67183
67180
67181
67186
67187
67220
67184
67185
67199
67190
67193
67194
67191
67192
67197
67198
67195
67196
67201
67169
67202
67200
67205
67206
67203
67204
67209
67207
67208
67179
67212
67213
67177
67210
67178
67211
67216
67217
67214
67215
67218
67219
67171
67172
67170
67175
67176
67173
67174
References_xml – ident: 67181
  doi: 10.1373/clinchem.2008.108225
– ident: 67185
  doi: 10.1158/1055-9965.EPI-14-0552
– ident: 67219
  doi: 10.1385/SCR:1:1:037
– ident: 67169
  doi: 10.1038/s41467-023-42585-9
– ident: 67176
  doi: 10.1038/nbt.2696
– ident: 67184
  doi: 10.1373/clinchem.2006.085043
– ident: 67221
  doi: 10.1016/j.cell.2006.07.024
– ident: 67187
  doi: 10.1016/j.jmoldx.2014.02.004
– ident: 67193
  doi: 10.1111/j.1467-2494.2007.00372.x
– ident: 67213
  doi: 10.1016/j.bbmt.2010.09.001
– ident: 67215
  doi: 10.1038/nature730
– ident: 67183
  doi: 10.1097/00007691-200108000-00004
– ident: 67186
  doi: 10.4236/ojepi.2015.51006
– ident: 67178
  doi: 10.1186/2041-2223-2-23
– ident: 67197
  doi: 10.1093/nar/9.17.4267
– ident: 67202
  doi: 10.1007/s11864-023-01089-w
– ident: 67170
  doi: 10.1371/journal.pone.0235146
– ident: 67174
  doi: 10.1093/nar/gkw520
– ident: 67209
  doi: 10.1038/s41409-020-0938-x
– ident: 67214
  doi: 10.1038/ncb1132
– ident: 67177
  doi: 10.1158/2159-8290.CD-11-0184
– ident: 67203
  doi: 10.1177/10760296221097969
– ident: 67204
  doi: 10.1182/bloodadvances.2020001636
– ident: 67196
  doi: 10.1016/j.ajhg.2020.01.008
– ident: 67210
  doi: 10.1164/rccm.200301-145OC
– ident: 67180
  doi: 10.1177/154405910608501215
– ident: 67175
– ident: 67222
  doi: 10.1006/excr.2000.5027
– ident: 67189
  doi: 10.3390/ijms21113900
– ident: 67172
  doi: 10.1038/nm.4333
– ident: 67171
  doi: 10.1016/j.vibspec.2018.09.004
– ident: 67179
– ident: 67217
  doi: 10.1016/S0002-9440(10)63203-8
– ident: 67194
  doi: 10.1016/j.aanat.2011.03.013
– ident: 67205
  doi: 10.1007/s00292-023-01234-0
– ident: 67173
  doi: 10.1016/j.jmoldx.2014.12.006
– ident: 67207
  doi: 10.1182/blood-2007-02-071423
– ident: 67191
  doi: 10.1097/PAS.0b013e3180335f65
– ident: 67188
  doi: 10.1038/s41598-018-31503-5
– ident: 67195
  doi: 10.1016/j.clindermatol.2013.06.006
– ident: 67200
  doi: 10.1016/j.tcb.2022.12.001
– ident: 67198
  doi: 10.1038/s41525-022-00285-1
– ident: 67218
  doi: 10.1016/S0140-6736(03)12894-2
– ident: 67199
  doi: 10.1371/journal.pone.0017581
– ident: 67190
  doi: 10.1158/1078-0432.1119.11.3
– ident: 67211
  doi: 10.1038/35018642
– ident: 67192
  doi: 10.1016/j.bbamcr.2013.06.010
– ident: 67206
  doi: 10.7554/eLife.66395
– ident: 67182
  doi: 10.3961/jpmph.2012.45.4.235
– ident: 67216
  doi: 10.1038/sj.leu.2403789
– ident: 67201
  doi: 10.1016/j.yjmcc.2021.07.004
– ident: 67220
  doi: 10.1038/nature00870
– ident: 67212
  doi: 10.1007/s004290050237
– ident: 67208
  doi: 10.1007/s12024-018-0057-9
SSID ssj0020997
Score 2.4618137
Snippet Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’...
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patient...
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients'...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 3269
SubjectTerms Hematologic Malignancy
Title Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
URI https://www.ncbi.nlm.nih.gov/pubmed/38450530
https://www.proquest.com/docview/2942188364
https://pubmed.ncbi.nlm.nih.gov/PMC11443392
https://doaj.org/article/573630d37d9c45eba9c9a98cee698cc8
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1592-8721
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0020997
  issn: 0390-6078
  databaseCode: KQ8
  dateStart: 19940101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1592-8721
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0020997
  issn: 0390-6078
  databaseCode: DOA
  dateStart: 19940101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1592-8721
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0020997
  issn: 0390-6078
  databaseCode: DIK
  dateStart: 19940101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1592-8721
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0020997
  issn: 0390-6078
  databaseCode: RPM
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLaZI-tmnDBEJvar16rXXcpgkhkJwayM3IemQNXm2JN4f--44k75IthVx68cGSkawZab6RZj4RcsoSQ4tkkgoEG1QYWVEtraRGBitYUD6wlJx8faMub8XVnbx7ctVXigkr9MBl4NBh54pXjs-ctkL61mirja5xbVf4tDnNF83YxpkaXa2UD5rPDzQ6R2gFS9IcR_TwbWESGeoqHTsw8ZXVCAHEjlHK3P3_Apx_x00-MUQXb8jrEUHCvPR8n7zw8YAcziO2tvwNXyDHdObN8gPy8no8Oj8kyzPf9zQ8eA8_buaQ0kogmq4H22eOhvsBzABlLx9WAWICs1haQtkBsS0kPtdlZ2EosYfQRViUv0zrJ2D17r7c9ju8JbcX5z_PLul41wK1YibXdMrQc3DGWlXZ1jmLg2KVt8ajjVOskq71DqGPnRruquBaIbTSLWpALZl1bsbfkb24iv4DgdBq00qHrq9I3PQzI23wXDrFzDSg1CaEbwa7sSMReboPo2_QIUkiajYiapKImiKiCaHbr34VIo5n6n9PctzWTTTa-QUqVzMqV_Occk3IyUYLGpx26SzFRL96HBqmBYKjmits6H3Rim1TvEbFl7yakHpHX3b6slsSu0Wm9kbvVHCErB__R--PyKs0ICX08BPZWz88-s8IodbtcZ4tx3lv6w_PWRzJ
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cell-free+DNA+from+nail+clippings+as+source+of+normal+control+for+genomic+studies+in+hematologic+malignancies&rft.jtitle=Haematologica+%28Roma%29&rft.au=Krystel-Whittemore%2C+Melissa&rft.au=Petrova-Drus%2C+Kseniya&rft.au=Ptashkin%2C+Ryan+N&rft.au=Ewalt%2C+Mark+D&rft.date=2024-10-01&rft.eissn=1592-8721&rft_id=info:doi/10.3324%2Fhaematol.2024.285054&rft_id=info%3Apmid%2F38450530&rft.externalDocID=38450530
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon